Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
October 16, 2008
Recent research developments in the direct inhibition of coagulation proteinases--inhibitors of the initiation phase
Brian L Henry, Umesh R Desai
Thrombosis Research
|
September 23, 2014
Sulfated low molecular weight lignins, allosteric inhibitors of coagulation proteinases via the heparin binding site, significantly alter the active site of thrombin and factor xa compared to heparin
Brian L Henry, Umesh R Desai
Expert Opinion on Drug Discovery
|
June 3, 2014
Discovery methodology for the development of direct factor VIIa inhibitors
Brian L Henry, Umesh R Desai
Reviews in Cardiovascular Medicine
|
September 27, 2016
A Review of the Clinical Subgroup Analyses From the RE-LY Trial
Rohit Kumar, Aref M Rahman, Brian L Henry
Journal of Intensive Care Medicine
|
July 10, 2014
Authors' Response
Brian L Henry, Rohit Kumar, Roy E Smith
Journal of Intensive Care Medicine
|
March 27, 2014
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience
Rohit Kumar, Roy E Smith, Brian L Henry
Journal of the American College of Cardiology
|
July 4, 2015
Mode of Death Prevention by Serelaxin
Brian L Henry, David S Schwartzman, Guy Salama
Clinical Nephrology. Case Studies
|
October 19, 2017
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function
Thin Thin Maw, Brian L Henry, Tripti Singh
Biochemical and Biophysical Research Communications
|
December 14, 2011
Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases
Brian L Henry, Jay N Thakkar, Aiye Liang, et al.
Thrombosis and Haemostasis
|
December 22, 2009
Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies
Brian L Henry, May Abdel Aziz, Qibing Zhou, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
October 16, 2008
Recent research developments in the direct inhibition of coagulation proteinases--inhibitors of the initiation phase
Brian L Henry, Umesh R Desai
Thrombosis Research
|
September 23, 2014
Sulfated low molecular weight lignins, allosteric inhibitors of coagulation proteinases via the heparin binding site, significantly alter the active site of thrombin and factor xa compared to heparin
Brian L Henry, Umesh R Desai
Expert Opinion on Drug Discovery
|
June 3, 2014
Discovery methodology for the development of direct factor VIIa inhibitors
Brian L Henry, Umesh R Desai
Reviews in Cardiovascular Medicine
|
September 27, 2016
A Review of the Clinical Subgroup Analyses From the RE-LY Trial
Rohit Kumar, Aref M Rahman, Brian L Henry
Journal of Intensive Care Medicine
|
July 10, 2014
Authors' Response
Brian L Henry, Rohit Kumar, Roy E Smith
Journal of Intensive Care Medicine
|
March 27, 2014
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience
Rohit Kumar, Roy E Smith, Brian L Henry
Journal of the American College of Cardiology
|
July 4, 2015
Mode of Death Prevention by Serelaxin
Brian L Henry, David S Schwartzman, Guy Salama
Clinical Nephrology. Case Studies
|
October 19, 2017
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function
Thin Thin Maw, Brian L Henry, Tripti Singh
Biochemical and Biophysical Research Communications
|
December 14, 2011
Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases
Brian L Henry, Jay N Thakkar, Aiye Liang, et al.
Thrombosis and Haemostasis
|
December 22, 2009
Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies
Brian L Henry, May Abdel Aziz, Qibing Zhou, et al.
Page
of 2